Long-Term Value Analysis of NAURA Technology Group

Whether the business is simple and transparent, and whether I would hold it if the stock market closed for five years. This business can be understood, but it is not easy. It is not a black box, but it is highly engineering-driven, and the threshold for understanding it is higher than for consumer goods or ordinary manufacturing. If the stock market closed for five years and the purchase price were low enough, I would be willing to own this business. But if I bought it today at more than roughly RMB 600, I would not feel very comfortable, because I would be holding a growth machine that is still consuming R&D, inventory, and working capital, rather than a mature asset already generating stable cash.

Business understandability score: 4/5.

Industry and competitive landscape. The semiconductor equipment industry is a typical growth industry with strong cyclical attributes. Data from SEMI and SEAJ show that the global equipment market reached record highs in both 2024 and 2025, with mainland China remaining the largest regional market for the sixth consecutive year in 2025 at USD 49.3 billion. At the same time, SEMI still forecasts growth for 2026-2027, supported mainly by logic, memory, and AI-related demand. In other words, this is an industry with rising long-term demand and large short- to medium-term volatility.

Who the main competitors are, and where the company stands. Globally, NAURA faces mature giants such as Applied Materials, Lam Research, Tokyo Electron, and KLA. Domestically, one of its strongest direct competitors in etching is AMEC; important competitors in thin-film deposition and ALD include Piotech and Wuxi Lead Intelligent's semiconductor-related peers such as micro/nano equipment companies, while important wet-process competitors include ACM Research Shanghai. NAURA's defining feature is not being the strongest at one single point, but having the broadest platform. The company's website product matrix and annual reports both show coverage across etching, deposition, furnaces, wet process, ion implantation, electroplating, bonding, and other key steps. Management has also emphasized that 2024 semiconductor equipment revenue was RMB 26.578 billion, with thin-film deposition equipment exceeding RMB 10 billion and etching equipment exceeding RMB 8 billion. Compared with global leaders, it is still clearly smaller. Management's reference figures were: 2024 revenue of USD 21.439 billion for Applied Materials, USD 12.753 billion for Lam, USD 12.651 billion for TEL, and about USD 4.133 billion in sales revenue for NAURA.

Whether the industry profit pool is concentrated and whether the company has pricing power. The industry profit pool is highly concentrated among leading equipment vendors and core process companies that can move through node upgrades. NAURA's pricing power is not consumer-brand-style pricing power. It is relative bargaining power from validation barriers, depth at key process steps, and platform synergy. But the margin decline in 2025 shows the company is not yet strong enough to fully pass on costs, competition, and product-mix changes to customers. My judgment is that it has above-average pricing power, but is far from a position where it can raise prices whenever it wants.

Industry attractiveness score: 4/5. This is a “good company in a good industry,” but not a “good industry where money comes in effortlessly.”

Moat and Management

First, the conclusion: NAURA's moat is real, but it is closer to “several medium-depth moats stacked together” than one extremely deep moat. Its most important barriers come from platform breadth, customer validation, process know-how, R&D talent, and local service capability, rather than brand premium or network effects.

The factual basis for the table mainly comes from the company's product matrix, patent and R&D disclosures, customer and platform descriptions, and management meeting notes. In 2025, the company maintained high R&D investment. Its annual report disclosed more than 11,300 cumulative patent applications and more than 6,500 granted patents; cumulative PVD tool deliveries surpassed 1,000 units; cumulative vertical furnace shipments surpassed 1,000 units; and R&D staff reached 6,511, accounting for 30.86% of employees. These all show that its moat is not a concept. It is attached to whether products can be developed, delivered in batches, and continue to receive customer orders after delivery.

Whether the moat is widening, stable, or narrowing. My judgment is: in the Chinese domestic market, it is widening overall; globally, it remains stable to slowly widening while still catching up. It is widening for three reasons. First, platform breadth continues to expand. Second, management has made clear that the acquisition of Kingsemi fills the gap in coating and developing. Third, more batch orders are coming from leading customers in memory, logic, and advanced packaging, which will strengthen subsequent validation stickiness.

How long and how much capital competitors would need to copy it. No company directly tells you this number in an annual report. But considering the company's product breadth, R&D intensity, customer validation, and industry entry barriers, my inference is: replicating a platform-style equipment vendor that can be validated for large-scale mass production at leading wafer fabs often requires more than 5-10 years of R&D and industrialization ramp-up, plus long-term capital investment of several billion to more than RMB 10 billion. This cannot be done simply by buying equipment and hiring a few hundred engineers, because the real difficulty lies in process coverage, stability, customer-side mass-production validation, and after-sales iteration. This judgment is an inference, but it is supported by the company's broad product line, high-intensity R&D, patent accumulation, and mass-production milestones.

Can it raise prices during inflation, and can it stay profitable in downturns. It has some ability to raise prices, but this mainly comes from scarcity and validation costs rather than brand premium, so pricing power is limited but not weak. As for staying profitable in downturns, at least based on the results from 2021-2025, the company remained profitable throughout. In 2025 it still achieved RMB 5.522 billion of net profit attributable to shareholders, and by the end of 2025 it was still close to a net-cash position with high interest coverage. Its survival capability is stronger than that of most high-tech growth stocks. But cash flow is quite volatile, meaning profit stability is stronger than cash stability.

Whether past high margins were structural advantage or cyclical tailwind. The answer is: both, but 2025 has already reminded you that you cannot linearly extrapolate the high margin of 2024. Margins improved materially in 2024 thanks to scale effects and falling expense ratios. In 2025, revenue still grew 30.85%, but operating margin fell from about 21.8% to about 14.7%, and net margin fell from about 18.7% to about 14.0%, showing margins do not only move in one direction.

Moat strength score: 3.5/5.

Now, management and capital allocation. On honesty, I rate it “above acceptable”; on shareholder alignment, “medium”; on capital-allocation rationality, “above medium.” The company's 2025 financial statements received a standard unqualified audit opinion, but the auditor listed “revenue recognition” and “recognition of development expenditure and R&D expenses” as key audit matters. This is not evidence of fraud, but it shows that the most important areas to watch in the financial statements are exactly the areas most prone to “beautification” or misreading at semiconductor equipment companies: revenue timing and R&D capitalization. Management also gave relatively direct answers in investor communication about cash-flow pressure, order trends, supply-chain prepayments, and acquisition logic. I think the level of candor is acceptable.

Whether interests are aligned with shareholders. NAURA is not founder-led. It has a clear state-owned capital background. At the end of 2025, the largest shareholder Beijing Sevenstar Huadian Technology Group held 33.20%, Beijing Electronics Holding held 9.31%, and the National IC Fund held 5.00%. Senior executives held only 579,400 restricted shares in total, suggesting management's “real-money shareholding” is not high. Alignment comes more from tenure assessment and equity incentives than from the Buffett-preferred model where management has most of its net worth in the same stock. For conservative value investors, this is a negative point.

How capital allocation has been. Three points deserve credit. First, R&D investment is determined and consistent with platform expansion. Second, dividends are moderate, and the company has not paid large dividends blindly during a high-investment phase. Third, there was no share repurchase during the 2025 reporting period, so it did not use buybacks to dress up EPS. On dividends, the company proposed cash dividends per 10 shares of RMB 7.80, RMB 10.60, and RMB 7.62 for 2023, 2024, and 2025 respectively, with an additional 3.5-for-10 capitalization issue in 2024. Based on each period's share base, cash dividends were about RMB 414 million, RMB 566 million, and RMB 553 million, all clearly below net profit attributable to shareholders for the period. Overall, this is growth-style allocation: heavy on R&D, light on dividends.

Whether acquisitions create value. The most important capital move in 2025 was the acquisition of control over Kingsemi. I recognize the strategic logic: it fills the coating and developing process step and improves platform completeness. Management also wrote this clearly in the annual report and IR answers. But the economic value cannot be declared a success in advance. In 2025, goodwill jumped from RMB 38 million to RMB 2.386 billion, and intangible assets also increased substantially. This means you must start taking future integration risk, synergy-delivery risk, and potential impairment risk seriously. Strategically, it looks like a widening of the moat; financially, it also raises the future “cost of being wrong.”

Management and capital allocation score: 3/5.

Financial Quality and Owner Earnings

First, the long-term financial profile. The table below is the most important factual base. One note is important: 2023-2025 use the retrospectively adjusted figures in the 2025 annual report; 2020-2022 use historical figures from the company website, so comparisons across 2022/2023 are not fully on the same basis. This does not change the big picture, but it affects the precise CAGR.

The data show three obvious features in recent years. First, growth has been very fast: by a rough 2020-2025 estimate, revenue CAGR was about 45%, and net profit attributable CAGR was about 59%. Second, profitability did improve, but it clearly fell back in 2025, showing high growth does not automatically equal high cash quality. Third, cash flow and profit do not match: over 2023-2025, operating cash flow / net profit attributable averaged only about 42%, far below the 80%-100% range common among high-quality cash cows. For a long-term business owner, this matters more than whether the PE is high or low.

Now, recent margins. In 2024, the company's gross margin was about 42.9%, operating margin about 21.8%, and net margin about 18.7%. By 2025, gross margin had fallen to about 40.1%, operating margin to about 14.7%, and net margin to about 14.0%. In Q1 2026, gross margin recovered to about 40.8%, but net profit attributable rose only about 3.4% year on year. The company explained that the main reason was continued increased investment in high-end equipment R&D, with R&D expenses recognized in profit or loss rising 36.64% year on year. This shows NAURA is still in a phase where revenue expansion takes priority over profit maximization.

Working-capital occupation is the most concerning point in current financial quality. At the end of 2025, the company had cash and monetary funds of RMB 17.337 billion, accounts receivable of RMB 8.217 billion, inventory of RMB 28.627 billion, accounts payable of RMB 11.803 billion, and contract liabilities of RMB 4.291 billion. Compared with the end of 2024, inventory increased by about RMB 4.992 billion, accounts receivable increased by about RMB 1.981 billion, while contract liabilities decreased by about RMB 1.929 billion. This set of changes is critical: it tells you that, to deliver and gain share, the company has effectively tied up a large amount of cash in inventory and working capital. At the 2025 results briefing, management also acknowledged that an important reason for tight cash flow was advance stocking to meet order demand, and that future cash-flow improvement would depend on increasing customer prepayment ratios, strengthening collection, and reducing raw-material stocking.

Whether the balance sheet is sound. The conclusion is: sound, but heavier than in recent years. At the end of 2025, total assets were RMB 89.801 billion and total liabilities were RMB 45.873 billion, implying a liability-to-asset ratio of about 51.1%. Interest-bearing debt was roughly about RMB 15 billion, while monetary funds were about RMB 17.3 billion, so the company was still close to a net-cash position overall. Based on 2025 EBIT and interest expense, interest coverage was roughly around 22 times, so short-term survival risk is very low. The real question is not “will something go wrong,” but “can these assets be converted into future cash flow at high returns?”

Capital-expenditure intensity and R&D capitalization. I need to be rigorous here. In management disclosures, the company said 2025 R&D investment was RMB 7.277 billion, accounting for 18.49% of revenue, with capitalized R&D investment of RMB 2.511 billion and a capitalization ratio of 34.50%. But the financial notes also disclosed that the “semiconductor equipment R&D project” incurred RMB 7.946 billion in the period, of which RMB 5.435 billion was expensed and RMB 2.511 billion was capitalized. The two sets of figures are not fully consistent. For estimating owner earnings, I prefer to use the financial-note basis, because it ties better to the R&D expense in the income statement. Whichever basis is used, the conclusion is the same: the company's real economic investment is far larger than the R&D expense line in the income statement.

Share count and shareholder returns. Share capital increased from the 530.9 million-share base used in the 2023 profit distribution plan, to 534.2 million shares in the 2024 plan, and then to 724.6 million shares on the 2025 balance sheet. The 3.5-for-10 capitalization issue in 2024 was share-capital expansion rather than real dilution; the true economic dilution mainly came from stock-option exercises. On equity incentives, the company launched several rounds of stock-option plans in 2019, 2022, and 2024. The 2022 plan initially granted 10.476 million options and reserved 2.60 million options; the 2024 plan granted 9.1543 million options. The plans covered many people, showing the incentives are broad-based and engineer-oriented, rather than a small group of executives enriching themselves. Overall, dilution exists, but has not yet reached an unacceptable level.

How to view accounting risk. I did not see direct evidence of financial fraud or a qualified audit opinion; on the contrary, the annual report received a standard unqualified opinion. But I would explicitly list two items as long-term tracking priorities: revenue recognition and recognition of development expenditure / R&D expenses. The auditor listed both as key audit matters, which itself means they are important enough to affect profit and the balance sheet, and therefore valuation conclusions. For conservative investors, this is not a veto, but it is definitely a discount factor.

Now comes the most important step: Owner Earnings.

If one uses a loose formula of “net profit + depreciation and amortization - maintenance capex,” the company's 2025 net profit attributable was about RMB 5.522 billion, depreciation, amortization, and long-term deferred amortization in the cash-flow statement notes totaled about RMB 1.567 billion, and if maintenance fixed-asset capex is conservatively estimated at RMB 600 million, then “loose-basis” owner earnings would seem to be around RMB 6 billion. But I do not accept that result. For a semiconductor equipment company, capitalized R&D is not a “free lunch.” It is real economic investment.

So I use two bases. Normalized basis: assume about 70% of 2025 capitalized R&D was necessary to maintain the competitive position, so about RMB 1.76 billion should be deducted additionally from owner earnings. On this basis, 2025 “normalized owner earnings before the year's abnormal working-capital occupation” were roughly RMB 4.7 billion. Strict cash basis: start directly from operating cash flow of RMB 2.133 billion, then deduct RMB 600 million of maintenance fixed-asset capex and about RMB 1.76 billion of maintenance capitalized R&D. On this strict basis, 2025 owner earnings were roughly close to zero to slightly negative. These two results look contradictory, but they are not. Together they point to one core fact: NAURA today looks more like a reinvestment machine with high-return potential than a mature company able to distribute stable cash.

Therefore, if you ask me what “conservative owner earnings” should be, my answer is: do not use 2025 net profit of RMB 5.5 billion, and do not use the extreme strict cash-basis value near zero; I would place steady-state conservative owner earnings at about RMB 4.0 billion. This figure is already meaningfully below net profit attributable for the year and reflects discounts for R&D capitalization and cash conversion. Based on the current market capitalization of about RMB 442.8 billion, that corresponds to about 111 times conservative owner earnings. Even using my more moderate neutral steady-state owner earnings of RMB 5.5 billion, the multiple is still about 80 times. This cannot be called cheap.

Valuation and Margin of Safety

First, the current market baseline. Because data-source timestamps differ, around June 3-4, 2026, NAURA's share price was roughly in the RMB 603-610 per share range. Google Finance showed total shares of about 725.65 million, market capitalization of about RMB 436.9 billion, and P/E of about 81.6 times. Yahoo Finance gave TTM P/E of about 76.6 times, P/S of about 10.3 times, P/B of about 10.9 times, and EV/EBITDA of about 73.5 times. For all valuation work below, I uniformly use RMB 610 per share and about RMB 442.8 billion market capitalization as approximations.

Method 1: Owner earnings discounting. To avoid mechanically extrapolating 2025's abnormal working-capital occupation forever, I use “steady-state owner earnings” rather than “strict cash-basis owner earnings.” But to stay conservative, I set starting points at RMB 4.0 billion, RMB 5.5 billion, and RMB 7.0 billion, corresponding to conservative, neutral, and optimistic scenarios. The assumptions are as follows: conservative scenario, 10-year CAGR of 14%, discount rate of 11%, terminal growth of 3%; neutral scenario, 16%, 10%, 3.5%; optimistic scenario, 18%, 9%, 4%. I also add year-end 2025 net cash of about RMB 2.3 billion. Based on these assumptions, I get the following approximate intrinsic values per share. The relevant balance-sheet, income-statement, and cash-flow data all come from the company's 2025 annual report and the latest market valuation data.

The meaning of this table is very direct: the current price is roughly equivalent to a level where the optimistic case is close to being priced in. In other words, the market is not selling NAURA to you as a company that “may succeed.” It is selling it as a company where “future long-term strength is highly likely to be realized.” For conservative investors, that is not comfortable pricing.

Method 2: Relative valuation. Compared with domestic growth peers, NAURA is not the most expensive one, but it is certainly not cheap in absolute terms. Yahoo / Reuters data show that NAURA's current TTM P/E is about 76.6 times, P/S about 10.3 times, and P/B about 10.9 times. AMEC is about 93.9 times, 19.5 times, and 10.5 times. Piotech is about 100.2 times, 23.8 times, and 22.8 times. ACM Research Shanghai is about 93.0 times, 14.5 times, and 7.6 times. Among mature global leaders, Applied Materials is about 46.1 times, 13.5 times, and 16.3 times; Lam Research about 63.2 times, 19.5 times, and 39.5 times; Tokyo Electron about 42.4 times, 10.0 times, and 11.7 times. The conclusion is: NAURA is not absurdly priced relative to high-growth domestic peers, but relative to global leaders that are more mature and more cash-generative, there is no obvious bargain.

Method 3: Asset or liquidation value. This company clearly should not be valued on liquidation value, but a liquidation lens can tell you how thin the downside protection is. At the end of 2025, net assets attributable to shareholders were about RMB 37.726 billion, corresponding to book value per share of about RMB 52.1. After further deducting goodwill and intangible assets, rough tangible net assets were about RMB 24.82 billion, corresponding to about RMB 34.3 per share. Net cash was about RMB 2.32 billion. This shows NAURA's investment value is almost entirely built on future earning power and competitive position, rather than an asset floor. You are buying the future, not factories and book value.

Combining the three methods, I give the following range judgments:

• Conservative intrinsic value range: RMB 160-220 per share

• Reasonable intrinsic value range: RMB 280-380 per share

• Optimistic intrinsic value range: RMB 500-650 per share

• Ideal buy price range: RMB 220-320 per share

• Acceptable holding price range: RMB 320-450 per share

• Clearly overvalued price range: above RMB 550 per share

At about RMB 610 per share, the current price carries a large premium to my conservative value, is roughly 60%-120% above reasonable value, and is merely close to fair relative to optimistic value, rather than substantially undervalued. Put differently: to buy it today, you must believe in the optimistic scenario, and you must believe in it for a long time. That is almost the opposite of a “margin of safety.”

Whether the margin of safety is adequate. My clear judgment is: it is not adequate. The most fragile assumption in the valuation is not “whether the company will grow,” but “whether the company can truly convert profit into cash while growing rapidly, and whether the market will continue to assign it a very high valuation multiple over the next decade.” If growth falls short of expectations, or margin recovery is slower than expected, or valuation falls from 70-80 times to 25-35 times, investors may experience quite substantial long-term low returns even if the company itself does not deteriorate.

Compared with indices, bonds, and other opportunities. This step is especially important. The current CSI 300 trailing P/E is roughly 15 times, and China's 10-year government bond yield is about 1.72%. NAURA's current static earnings yield is only about 1.2%-1.3%. This means that if you look only at current earnings yield and valuation, NAURA is not more attractive than risk-free bonds. It remains worth discussing only because the market believes its earnings many years from now will be far higher than today. For capital allocation, the biggest opportunity cost in this kind of stock is not “will it rise,” but “are you locking capital into a good company that already requires optimistic assumptions to work, instead of buying cheaper good assets or an easier index?” Given your risk preference, my answer is: at the current price, it does not have clearly better certainty than buying the CSI 300 or waiting for a better price.

Risks, Checklist, and Final Judgment

I would rank the most important risks by thinking about “permanent capital loss,” not short-term share-price volatility.

• Overvaluation risk. This is the most direct current risk. The market has already assigned roughly 70-80 times TTM PE and more than 10 times P/S. Once growth slows, valuation compression itself could cause a prolonged capital drawdown.

• Cash-flow conversion risk. Operating cash flow was significantly below profit in 2023-2025, and changes in inventory, receivables, and contract liabilities in 2025 again show that profit does not equal distributable cash.

• Technology competition risk. Key process steps such as etching, deposition, cleaning, coating, and developing face both global giants and excellent domestic peers. Platform breadth is an advantage, but it also means a long R&D front line.

• R&D capitalization and accounting risk. The auditor listed revenue recognition and recognition of development expenditure and R&D expenses as key audit matters. The balance of development expenditure reached RMB 6.716 billion. If future project commercialization falls short of expectations, the company may face impairment or amortization pressure.

• Acquisition integration risk. The acquisition of Kingsemi strategically fills out the platform, but it also caused goodwill to rise visibly. Poor integration would damage returns.

• Industry cycle risk. SEMI data support long-term growth, but China's 2025 equipment investment was still expected to decline year on year. The industry does not rise in a straight line.

• Supply-chain and geopolitical risk. The company has disclosed prepayments to overseas suppliers, while the overall industry is affected by export controls and substitution progress.

• Customer validation and concentration risk. Leading-customer validation is a source of moat and a source of risk. If process substitution at key customers advances more slowly than expected, growth speed will be affected. Exact customer concentration data still need supplementary information from this review.

The strongest bear case. I think the truly strong short thesis is not “NAURA is poor,” but: NAURA is very good, yet the market has already priced it as China's future absolute core equipment company, with sustained high growth and eventual major cash-flow improvement. If any one of the following occurs in the next few years, the result could easily be “the company remains excellent, but shareholder returns are mediocre or even poor”: domestic mature-node capex slows; advanced-node validation progress falls short; customer prepayment ratios continue to decline; capitalized R&D stays high while cash flow does not improve for a long time; acquisition synergies fall short of expectations. For a high-valuation growth stock, that is enough to create permanent capital loss.

What facts would overturn the current analysis. If, over the next two to three years, the company can simultaneously achieve the following: first, revenue still maintains mid- to high-teens growth; second, operating cash flow / net profit meaningfully recovers to 70%-80%; third, the capitalized R&D ratio falls or its returns are clearly validated by orders; fourth, post-Kingsemi integration platform synergy truly raises single-customer penetration and margins; fifth, even amid industry volatility, the company can maintain ROIC above 18%, then I would raise my assessment of its intrinsic value and moat strength. Conversely, if inventory impairments increase significantly, development expenditure keeps swelling while commercialization slows, or margins collapse sharply during an industry downturn, I would admit my previous view was too optimistic.

Investment Checklist

The judgments in this table are mainly based on the company's annual reports, quarterly reports, investor-relations notes, industry data, and current valuation data.

Final Investment Conclusion

【Final Rating】 Watch

【One-Sentence Investment Thesis】 NAURA is one of China's semiconductor equipment platform companies most worth tracking over the long term, but at present it looks more like “an expensive quote for an excellent business” than “a value purchase with a margin of safety.”

【Core Bullish Reasons】

• Semiconductor equipment is a high-barrier, long-cycle track with large domestic-substitution room, and mainland China remains the world's largest equipment market.

• NAURA's advantage is not one single piece of equipment, but platform capability and breadth of process coverage.

• R&D investment, patent accumulation, R&D staff ratio, and mass-production delivery milestones support the reality of its technical barriers.

• The balance sheet is generally sound, with no short-term financial survival problem.

• If the Kingsemi acquisition is integrated smoothly, it could further complete the platform capability.

【Core Bearish Reasons】

• Current valuation is high, the margin of safety is insufficient, and the price is already close to the optimistic scenario.

• Free cash flow and distributable cash flow are significantly weaker than accounting profit, showing weak cash conversion.

• Margins fell visibly in 2025, showing high margins are not locked in.

• R&D capitalization and revenue recognition are audit focus areas and must continue to be treated with a discount.

• Acquisition risk combined with the industry cycle increases future execution uncertainty.

【Key Assumptions】

• Domestic wafer-fab capex does not undergo a sustained cliff-like contraction over the medium to long term.

• NAURA continues to improve process coverage and mass-production penetration in key steps such as etching, deposition, furnaces, cleaning, coating, and developing.

• Capitalized R&D ultimately converts into orders, revenue, and cash, rather than future impairments.

• Kingsemi acquisition synergies are realized, rather than merely bringing goodwill.

• The industry valuation center does not compress sharply to mature-manufacturing-stock levels in the next few years.

【Fair Buy Price】 I think the more comfortable long-term buy range is RMB 220-320 per share. The basis is that this range roughly corresponds to my reasonable intrinsic value range after applying a discount, and is closer to a price that leaves conservative investors a 20%-30% margin of safety.

【Target Holding Period】 At least 5-10 years. This is not an asset to judge by quarterly volatility. It should be judged by whether platform capability, process coverage, cash conversion, and returns on capital can keep improving.

【Expected Annualized Return】 I use a simple 10-year scenario calculation: if buying at the current price, under the conservative scenario with a 10-year net-profit CAGR of 8% and exit PE of 25 times, the expected annualized return is about -4% to -3%; under the neutral scenario with 10-year CAGR of 15% and exit PE of 30 times, about 4% to 5%; under the optimistic scenario with 10-year CAGR of 20% and exit PE of 35 times, about 10% to 11%. In other words, only the optimistic scenario justifies today's price. This calculation is based on the current market capitalization, 2025 profit base, and a low-dividend-yield approximation. It should not be treated as a precise forecast.

【Maximum Loss Risk】 If the industry cycle weakens, cash flow keeps failing to materialize, acquisition integration is poor, capitalized R&D leads to later impairments, and valuation returns to the conservative value range, a share-price decline to RMB 150-250 per share is not unimaginable. Compared with the current price above roughly RMB 600, that implies about 60%-75% downside risk. This is not the scenario I consider most likely, but it is a real “permanent capital loss” scenario.

【Tracking Indicators】

• Share of semiconductor equipment revenue and growth in detailed equipment categories such as etching, deposition, furnaces, cleaning, coating, and developing.

• Operating cash flow / net profit attributable.

• Changes in inventory, accounts receivable, and contract liabilities.

• Capitalized R&D amount, capitalization ratio, and development expenditure balance.

• Gross margin, operating margin, and ROIC.

• Post-Kingsemi integration synergies and changes in goodwill.

• Leading-customer mass-production adoption progress and new order trends.

• Prepayments to overseas suppliers and dependence on key components.

• Difference between the 10-year government bond yield and the company's earnings yield.

• Industry capex and mainland China equipment-investment prosperity.

【Signals That Would Trigger Reassessment】

• Operating cash flow remains obviously weaker than profit for more than two consecutive years with no signs of improvement.

• Inventory growth stays above revenue growth for a long period, and impairments increase.

• Capitalized R&D continues to rise, but orders and revenue fail to follow.

• Core equipment loses momentum or is replaced during validation at leading customers.

• Kingsemi integration fails to bring customer synergy and instead erodes margins.

• Valuation keeps rising without synchronized fundamental improvement.

• The balance sheet moves from near net cash to clear net debt.

【Final Recommendation】 If you are looking at NAURA with the mindset of “acquiring a business for the long term,” I would say: put it on your high-quality watchlist, not immediately into your high-conviction position list. The company deserves respect and long-term research. But for balanced and relatively conservative long-term capital, the decisive factor is not recognizing a good company, but refusing to pay too high a price for one. Today's NAURA is closer to “good company, bad price.” Waiting for better odds is more consistent with long-term value-investing discipline than rushing to own it.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.